Multiple sclerosis and environmental factors: The role of vitamin D, parasites, and Epstein-Barr virus infection

Acta Neurologica Scandinavica

Volumn 132, Issue S199, 2015, Pages 46-55

  Correale, J ^a   Gaitan M I ^a  

^a FLENI   (Argentina)

Author keywords

Environmental factors; Epstein Barr virus; Helminth infections; Hygiene hypothesis; Multiple sclerosis; Vitamin D

Indexed keywords

VITAMIN D;

B LYMPHOCYTE; CELL SURVIVAL; DISEASE COURSE; DOWN REGULATION; ENVIRONMENTAL FACTOR; EPSTEIN BARR VIRUS INFECTION; HELMINTHIASIS; HUMAN; HYGIENE HYPOTHESIS; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INVESTIGATIVE PROCEDURES; MULTIPLE SCLEROSIS; NONHUMAN; REVIEW; VITAMIN D DEFICIENCY; COMPLICATION; ENVIRONMENT; EPSTEIN-BARR VIRUS INFECTIONS; IMMUNE SYSTEM; NUTRITIONAL STATUS; PARASITIC DISEASES; PHYSIOLOGY;

ENVIRONMENT; EPSTEIN-BARR VIRUS INFECTIONS; HELMINTHIASIS; HUMANS; IMMUNE SYSTEM; MULTIPLE SCLEROSIS; NUTRITIONAL STATUS; PARASITIC DISEASES; VITAMIN D;

EID: 84930408700     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12431     Document Type: Review

References (98)

1. McFarland HF, Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 2007;8:913-9.
2. Oksenberg JR, Baranzini SE, Sawcer S, Hauser SL. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat Rev Genet 2008;9:516-26.
3. Gourraud PA, Harbo HF, Hauser SL, Baranzini SE. The genetics of multiple sclerosis: an up-to-date review. Immunol Rev 2012;248:122-39.
4. Ebers GC, Bulman DE, Sadovnik AD et al. A population-based study of multiple sclerosis in twins. N Engl J Med 1986;315:1638-42.
5. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part II: noninfectious factors. Ann Neurol 2007;61:504-13.
6. Riise T, Groonning M, Klauber MR, Barret-Connor E, Nyland H, Albreksten G. Clustering of residence of multiple sclerosis patients at age 13 to 20 in Hordaland, Norway. Am J Epidemiol 1991;133:932-9.
7. Pugliatti M, Riise T, Sotgiu MA et al. Evidence of early childhood as the susceptibility period in multiple sclerosis: space-time cluster analysis in Sardinian population. Am J Epidemiol 2006;164:326-33.
8. Melcon MO, Correale J, Melcon CM. Is it time for a new global classification of multiple sclerosis? J Neurol Sci 2014;344:171-81.
9. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol 2007;61:504-13.
10. Ascherio A. Environmental factors in multiple sclerosis. Expert Rev Neurother 2013;13(12 Suppl):3-9.
11. Correale J, Farez M. Association between parasite infection and immune responses in multiple sclerosis. Ann Neurol 2007;61:97-108.
12. Holick M. Vitamin D. In: Shils ME et al., eds. Modern nutrition in health and disease. Philadelphia: Williams and Wilkins, 2006;376-95.
13. Hayes CE, Nashold FE, Mayne CG, Spanier JA, Nelson CD. Vitamin D and multiple sclerosis. In: Feldman D, Pike JW, Adams JS, eds. Vitamin D. San Diego: Elsevier, 2011;1843-77.
14. van der Mei IA, Ponsonby AL, Bizzard L, Dwyer T. Regional variation in multiple sclerosis prevalence in Australia and its association with ambient ultraviolet radiation. Neuroepidemiology 2001;20:168-74.
15. Munger KL, Zhang SM, O'Reilly E et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004;62:60-5.
16. Holmøy T, Torkildsen Ø, Myhr KM, Løken-Amsrud KI. Vitamin D supplementation and monitoring in multiple sclerosis: who, when and wherefore. Acta Neurol Scand Suppl 2012;195:63-9.
17. Simpson S Jr, Taylor B, Bizzard A et al. Higher 25-hydroxyvitamin D is associated with lower relapses in multiple sclerosis. Ann Neurol 2010;68:193-203.
18. Mowry EM, Waubant E, McCulloch CE et al. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol 2012;72:234-40.
19. Correale J, Ysrraelit MC, Gaitán MI. Immunomodulatory effects of vitamin D in multiple sclerosis. Brain 2009;132:1146-60.
20. van der Mei IA, Ponsonby AL, Dwyer T et al. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol 2007;254:581-90.
21. Ramagopalan SV, Dyment DA, Cader MZ et al. Rare variants in the CYP27B1 gene are associated with multiple sclerosis. Ann Neurol 2011;70:881-6.
22. Ramagopalan SV, MAugeri V, Handunnetthi L et al. Expression of the multiple sclerosis-associated MHC class II allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet 2009;5:e10000369.
23. Lemire JM, Archer DC. 1, 25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest 1991;87:1103-7.
24. Cantorna MT, Hayes CE, DeLuca HF. 1, 25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci USA 1996;93:7861-4.
25. Adorini L, Penna G. Control of immune diseases by the vitamin D endocrine system. Nat Clin Pract Rheumatol 2008;4:404-12.
26. Norman AW. Receptors for 1-α, 25(OH)2D3: past, present, and future. J Bone Miner Res 1998;13:1360-9.
27. Veldman CM, Cantorna MT, DeLuca HF. Expression of 1, 25-dihydroxyvitamin D3 receptor in the immune system. Arch Biochem Biophys 2000;374:334-8.
28. Norman AW. Minireview: vitamin D receptor: new assignments for an already busy receptor. Endocrinology 2006;147:5542-8.
29. 3 on human B cell differentiation. J Immunol 2007;179:1634-47.
30. Ban Y, Taniyama M, Ban Y. Vitamin D receptor gene polymorphism is associated with Graves' disease in the Japanese population. J Clin Endocrinol Metab 2000;85:4639-43.
31. Hewison M, Burke F, Evans KN et al. Extra-renal 25-hydroxyvitamin D3-1α-hydroxylase in human health and disease. J Steroid Biochem Mol Biol 2007;103:316-21.
32. Hewison M, Freeman L, Hufghes SV et al. Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells. J Immunol 2003;170:5382-90.
33. Overbergh L, Stoffels K, Waer M, Verstuyf A, Bouillon R, Mathieu C. Immune regulation of 25-hydroxyvitamin D-1-α-hydroxylase in human monocytic THP1 cells: mechanisms of interferon-γ-mediated induction. J Clin Endocrinol Metab 2006;91:3566-74.
34. Dong X, Lutz W, Shroeder TM, Bachman LA et al. Regulation of relB in dendritic cells by means of modulated association of vitamin D receptor and histone deacetylase 3 with the promoter. Proc Natl Acad Sci USA 2005;102:16007-12.
35. Muthian G, Raikwar HP, Rajasingh J, Bright JJ. 1, 25 Dihydroxyvitamin-D3 modulates JAK-STAT pathway in IL-12/IFNγ axis leading to Th1 responses in experimental allergic encephalomyelitis. J Neurosci Res 2006;83:1299-309.
36. Li P, Li C, Zhao X, Zhang X, Nicosia SV, Bai W. p27 (kip1) stabilization and G(1) arrest by 1, 25-dihydroxyvitamin D3 in ovarian cancer cells mediated through down-regulation of cyclin E/cyclin-dependent kinase 2 and Skp1-cullin-F-box protein/Skp2 ubiquitin ligase. J Biol Chem 2004;279:25260-7.
37. Mayne CG, Spanier JA, Relland LM, Williams CB, Hayes CE. 1, 25-dihydroxyvitamin D3 acts directly on the T lymphocyte vitamin D receptor to inhibit experimental autoimmune encephalomyelitis. Eur J Immunol 2011;41:822-32.
38. Penna G, Adorini G. 1α, 25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000;164:2405-11.
39. Adorini L, Giarratana N, Penna G. Pharmacological induction of tolerogenic dendritic cells and regulatory T cells. Semin Immunol 2004;16:127-34.
40. Gregori S, Casorati M, Amuchastegui S, Smiroldo S, Davalli AM, Adorini L. Regulatory T cells induced by 1α, 25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol 2001;167:1945-53.
41. Casteels K, Waer M, Laureys J et al. Prevention of autoimmune destruction of syngeneic islet grafts in spontaneously diabetic nonobese diabetic mice by a combination of a vitamin D3 analog and cyclosporine. Transplantation 1998;65:1225-32.
42. D'Ambrosio D, Cippitelli M, Cocciolo MG et al. Inhibition of IL-12 production by 1, 25 dihydroxyvitamin D3. Involvement of NF-κB downregulation in transcriptional repression of the p40 gene. J Clin Invest 1998;101:252-62.
43. Spach KM, Nashold FE, Dittel BN, Hayes CE. IL-10 signaling is essential for 1, 25-dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis. J Immunol 2006;177:6030-7.
44. Penna G, Amuchastegui S, Cossetti C et al. Treatment of experimental autoimmune prostatitis in nonobese diabetic mice by the vitamin D receptor agonist elocalcitol. J Immunol 2006;177:8504-11.
45. Adorini L. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting autoimmune diabetes. Ann N Y Acad Sci 2003;987:258-61.
46. Penna G, Amuchastegui S, Giarratana N et al. 1, 25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells. J Immunol 2007;178:145-53.
47. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9.
48. Correale J, Ysrraelit MC, Gaitán MI. Gender differences in 1, 25 dihydroxyvitamin D3 immunomodulatory effects in multiple sclerosis patients and healthy subjects. J Immunol 2010;185:4948-58.
49. Spach KM, Hates CE. Vitamin D3 confers protection from autoimmune encephalomyelitis only in female mice. J Immunol 2005;175:4119-26.
50. Christen U, von Herrath MG. Infections and autoimmunity - good or bad? J Immunol 2005;174:7481-6.
51. Correale J, Fiol M, Gilmore W. The risk of relapses in multiple sclerosis during systemic infections. Neurology 2006;67:652-9.
52. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002;347:911-20.
53. Leibowitz U, Atanovsky A, Medalie JM, Smith HA, Halpern L, Alter M. Epidemiological study of multiple sclerosis in Israel. II. Multiple sclerosis and the level of sanitation. J Neurol Neurosurg Psychiatry 1996;29:60-8.
54. Fleming JO, Cook TD. Multiple sclerosis and the hygiene hypothesis. Neurology 2006;67:2085-6.
55. Cabre P, Signate A, Olindo S, Merle H et al. Role of return migration in the emergence of multiple sclerosis in the French West Indies. Brain 2005;128:2899-910.
56. van den Bigeelar AH, Rodrigues LC, van Ree R et al. Long-term treatment of intestinal helminthes increases mite skin-test reactivity in Gabonese schoolchildren. J Infect Dis 2004;189:892-900.
57. Correale J, Farez M. The impact of parasite infections on the course of multiple sclerosis. J Neuroimmunol 2011;233:6-11.
58. Wammes LJ, Mpairve H, Elliot AM, Yazdanbaksh M. Helminth therapy or elimination: epidemiological, immunological and clinical considerations. Lancet Infect Dis 2014;14:1150-62.
59. Sewell D, Qing Z, Reinke E et al. Immunomodulation of experimental autoimmune encephalomyelitis by helminth ova immunization. Int Immunol 2003;15:59-69.
60. La Flamme AC, Ruddenklau K, Bäckström BT. Schistosomiasis decreases central nervous system inflammation and alters the progression of experimental autoimmune encephalomyelitis. Infect Immun 2003;71:4996-5004.
61. Walsh KP, Brady MT, Finlay CM, Boon L, Mills KHG. Infection with helminth parasite attenuates autoimmunity through TGF-β-mediated suppression of Th17 and Th1 responses. J Immunol 2009;183:1577-86.
62. Correale J, Farez M, Razzitte G. Helminth infections associated with multiple sclerosis induce regulatory B cells. Ann Neurol 2008;64:187-99.
63. Fillatreau S, Sweenie CH, McGeachy MJ, Gary D, Anderton SM. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002;3:944-50.
64. Godfrey DI, Kroneneberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest 2004;114:1379-88.
65. Colgan SP, Hersberg RM, Furuta GT, Blumberg RS. Ligation of intestinal epithelial CD1d induces bioactive IL-10: critical role of cytoplasmic tail in autocrine signaling. Proc Natl Acad Sci USA 1999;96:13938-43.
66. Maden M. Retinoic acid in the development, regeneration and maintenance of the nervous system. Nat Rev Neurosci 2007;8:755-65.
67. Royal W 3rd, Gardner S, Gajewski CD. Retinol measurements and retinoid receptor gene expression in patients with multiple sclerosis. Mult Scler 2002;8:452-8.
68. Løken-Amsrud K, Myhr K-M, Bakke SJ et al. Retinol levels are associated with magnetic resonance imaging outcomes in multiple sclerosis. Mult Scler J 2013;19:451-7.
69. Correale J, Farez M. Parasite infections in multiple sclerosis modulate immune responses through a retinoic acid-dependent pathway. J Immunol 2013;191:3827-37.
70. Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol 2001;1:75-82.
71. Lossius A, Riise T, Pugliatti M et al. Season of infectious mononucleosis and risk of multiple sclerosis at different latitudes; the EnvIMS Study. Mult Scler 2014;20:669-74.
72. Warner HB, Carp RI. Multiple sclerosis and Epstein-Barr virus. Lancet 1981;2:1290.
73. Nielsen TR, Rostgaard K, Nielsen NM et al. Multiple sclerosis after infectious mononucleosis. Arch Neurol 2007;64:72-5.
74. Sumaya CV, Myers LW, Ellison GW. Epstein-Barr virus antibodies in multiple sclerosis. Arch Neurol 1980;37:94-6.
75. Santiago O, Gutierrez J, Sorlozano A, de Dios Luna J, Villegas E, Fernandez O. Relation between Epstein-Barr virus and multiple sclerosis: analytic study of scientific production. Eur J Clin Microbiol Infect Dis 2010;29:857-66.
76. Ascherio A, Munger KL, Lennette ET et al. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 2001;286:3083-8.
77. Sundström P, Juto P, Wadell G et al. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology 2004;62:2277-82.
78. Levin LI, Munger KL, Rubertone MV et al. Temporal relationship between elevation of Epstein-Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 2005;293:2496-500.
79. Jilek S, Schluep M, Meylan P et al. Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis. Brain 2008;131:1712-21.
80. Lunemann JD, Edwards N, Muraro PA et al. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain 2006;129:1493-506.
81. Angelini DF, Serafini B, Piras E et al. Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis. PLoS Pathog 2013;9:e1003220.
82. Serafini B, Rosicarelli B, Franciotta D et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 2007;204:2899-912.
83. Magliozzi R, Howell O, Vora A et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007;130:1089-104.
84. Magliozzi R, Serafini B, Rosicarelli B et al. B-cell enrichment and Epstein-Barr virus infection in inflammatory cortical lesions in secondary progressive multiple sclerosis. J Neurpathol and Exp Neurol 2013;72:29-41.
85. Lunemann JD, Tintore M, Messmer B et al. Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. Ann Neurol 2010;67:159-69.
86. Farrell RA, Antony D, Wall GR et al. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology 2009;73:32-8.
87. Zivadinov R, Zorzon M, Weinstock-Guttman B et al. Epstein-Barr virus is associated with grey matter atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry 2009;80:620-5.
88. Hollsberg P, Hansen HJ, Haahr S. Altered CD8+ T cell responses to selected Epstein-Barr virus immunodominant epitopes in patients with multiple sclerosis. Clin Exp Immunol 2003;132:137-43.
89. Rand KH, Houck H, Denslow ND, Heilman KM. Epstein-Barr virus nuclear antigen-1 (EBNA-1) associated oligoclonal bands in patients with multiple sclerosis. J Neurol Sci 2000;173:32-9.
90. Lünemann JD, Munz C. EBV in MS: guilty by association? Trends Immunol 2009;30:243-8.
91. Lünemann JD, Jelcić I, Roberts S et al. EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-γ and IL-2. J Exp Med 2008;205:1763-73.
92. Sutkowski N, Palkama T, Ciurli C, Sekaly RP, Thorley-Lawson DA, Huber BT. An Epstein-Barr virus-associated superantigen. J Exp Med 1996;184:971-80.
93. Sutkowski N, Conrad B, Thorley-Lawson DA, Huber BT. Epstein-Barr virus transactivates the human endogenous retrovirus HERV-K18 that encodes a superantigen. Immunity 2001;15:579-89.
94. van Noort JM, Bajramovic JJ, Plomp AC, van Stipdonk MJ. Mistaken self, a novel model that links microbial infections with myelin-directed autoimmunity in multiple sclerosis. J Neuroimmunol 2000;105:46-57.
95. Pender MP. Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends Immunol 2003;24:584-8.
96. Iwakiri D, Zhou L, Samanta M et al. Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-infected cells and activates signaling from Toll-like receptor 3. J Exp Med 2009;206:2091-9.
97. Recher M, Lang KS, Navarini A et al. Extralymphatic virus sanctuaries as a consequence of potent T-cell activation. Nat Med 2007;13:1316-23.
98. Jons D, Sundström P, Andersen O. Targeting Epstein-Barr virus as an intervention against multiple sclerosis. Acta Neurol Scand 2015;131:69-79.